Fibrocalcific Aortic Valve Disease: Opportunity to Understand Disease Mechanisms Using Mouse Models
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Studies in vitro and in vivo continue to identify complex-regulated mechanisms leading to overt fibrocalcific aortic valve disease (FCAVD). Assessment of the functional impact of those processes requires careful studies of models of FCAVD in vivo. Although the genetic basis for FCAVD is unknown for most patients with FCAVD, several disease-associated genes have been identified in humans and mice. Some gene products which regulate valve development in utero also protect against fibrocalcific disease during postnatal aging. Valve calcification can occur via processes that resemble bone formation. But valve calcification can also occur by nonosteogenic mechanisms, such as formation of calcific apoptotic nodules. Anticalcific interventions might preferentially target either osteogenic or nonosteogenic calcification. Although FCAVD and atherosclerosis share several risk factors and mechanisms, there are fundamental differences between arteries and the aortic valve, with respect to disease mechanisms and responses to therapeutic interventions. Both innate and acquired immunity are likely to contribute to FCAVD. Angiogenesis is a feature of inflammation, but may also contribute independently to progression of FCAVD, possibly by actions of pericytes that are associated with new blood vessels. Several therapeutic interventions seem to be effective in attenuating the development of FCAVD in mice. Therapies which are effective early in the course of FCAVD, however, are not necessarily effective in established disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“osteoclasts, which critically regulate tissue mineralization in bone.(92,93) It is not known, however, whether M-CSF regulates”
BackgroundJaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Environmental epigenomics and disease susceptibility
Jirtle, R. L., & Skinner, M. K. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2045 · Cited by 2,492
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Mutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Freeman, R. V., & Otto, C. M. (2005) · Circulation · doi:10.1161/circulationaha.104.486738 · Cited by 1,006 · cited 4×
“Asymmetry of Aortic Valve Endothelium and Shear Stress In humans, FCAVD usually begins on the aortic side of valve cusps, with relative sparing of the ventricular side, which is exposed to high shear induced by ejection of ventricular blood.(19) Recently, several investigators have sought to identify Figure 1.”
BackgroundInfluentialRoberts, W. C., & Ko, J. M. (2005) · Circulation · doi:10.1161/01.cir.0000155623.48408.c5 · Cited by 1,000 · cited 2×
“209 Fibrocalcific aortic valve disease (FCAVD) is a growing health problem in the developed world.(1,2) The incidence of overt FCAVD rises exponentially with age, with a steep increase after 65 years of age.”
Background
Cited by
Association Between Cardiovascular Risk Factors and Aortic Stenosis
Yan, A. T., Koh, M., Chan, K. K., Guo, H., Alter, D. A., Austin, P. C., Tu, J. V., Wijeysundera, H. C., & Ko, D. T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.025 · Cited by 247
Transcriptional profiling of normal, stenotic, and regurgitant human aortic valves
Greene, C. L., Jaatinen, K. J., Wang, H., Koyano, T. K., Bilbao, M. S., & Woo, Y. J. (2020) · Genes · doi:10.3390/genes11070789 · Cited by 30
Influence of cusp morphology and sex on quantitative valve composition in severe aortic stenosis
Patel, K. P., Lin, A., Kumar, N., Esposito, G., Grodecki, K., Lloyd, G., Mathur, A., Baumbach, A., Mullen, M. J., Williams, M. C., et al. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead142 · Cited by 21
Liu, M., Luo, M., Sun, H., Ni, B., & Shao, Y. (2017) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.243.263 · Cited by 20
“However, it may contribute to the progression of CAVD and, therefore, may be a key step in valve calcification (Weiss et al. 2013).”
BackgroundInfluential
Metadata
- Authors
- Weiss, R. M., Miller, J. D., & Heistad, D. D.
- Venue
- Circulation Research
- Published
- 2013-07-05
- Volume
- 113
- Issue
- 2
- Pages
- 209-222
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2107758711
- Cited by
- 102
- References
- 17
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrocalcific Aortic Valve Disease: Opportunity to Understand Disease Mechanisms Using Mouse Models. https://app.cochat.ai/papers/10.1161/circresaha.113.300153
- The paper
- Weiss, R. M., Miller, J. D., & Heistad, D. D. (2013). Fibrocalcific Aortic Valve Disease: Opportunity to Understand Disease Mechanisms Using Mouse Models. Circulation Research. https://doi.org/10.1161/circresaha.113.300153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.